Product Description
Mechanisms of Action: SQS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Egypt | India | Japan
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: China, Unknown Location
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Osteoporosis|Osteoporosis, Postmenopausal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20220817 | P3 |
Not yet recruiting |
Osteoporosis |
None |
|
CTR20171286 | P1 |
Not yet recruiting |
Osteoporosis |
None |
|
CTR20170793 | P3 |
Not yet recruiting |
Osteoporosis, Postmenopausal |
None |
|
CTR20180989 | P1 |
Not yet recruiting |
Osteoporosis, Postmenopausal |
None |